A most welcomed simplification
Europlasma simplifies its corporate set up. The group will now own its power generation units and can crystallise the “hidden” value of those assets in the simplification process. Europlasma should…
Transition year is behind, brighter outlook
After a difficult year of transition for Keyware, which was mainly seen through the Payment Terminal (PT) division’s lower revenues and profitability, we have decreased our earnings forecasts for the…
On its way to reach the market…
Crossject released its FY17 results. Revenues came in at €4.14m vs €1.43m, operating result €-8,621k (vs €-7,291k), and net result €-7,611k (vs €-6,663k). Net cash at the end of FY17…
Strong operations confirm regime change
Chargeurs released FY 2017 earnings that show a strong operating performance and exude confidence with a dividend at €0.6, above expectations. Chargeurs has released very satisfactory full-year earnings with a…
FY17 – a transition year
Keyware reported its FY17 results, with revenues flat yoy to €18,730k. The drop in revenues from the Payment terminals division (-24% to €8,449k) was compensated by the increase in revenues…
Plasma to help clean up steelmaking
Europlasma sees a long-term market in applying plasma-based clean-up know-how to steel furnaces. Revenue prospects and timetable are not available. Europlasma has announced a technical breakthrough. It plans to deploy…
A convertible bond and options for existing shareholders
Crossject announced the granting of free options (“BSA”) to existing shareholders as well as the issue of a convertible bond (€5.25m). Existing shareholders will be granted one option for ten…
Fresh and less expensive round of financing
Europlasma collects another €8m of fresh financing. It broadly relies on the same financing mechanics as deployed in a 2016-17 round: issuance of immediately converted convertibles at a discount to…
Orphan disease status for Zeneo® Midazolam in the US
The group indicated it had obtained orphan drug status for Zeneo® Midazolam from the FDA for the treatment of “status epilepticus”, i.e. epileptic crises of over five minutes. Orphan drug…
Allowing for 2017 financing
The sharp drop in the target price is due to an overdue set of adjustments that combines the H1 17 release and the dilution associated with financing, as well as…